# Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

> **NCT01228331** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 745 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Amsacrine
- **DRUG:** Clofarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Etoposide phosphate
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Methylprednisolone
- **DRUG:** Pegaspargase
- **DRUG:** Thioguanine
- **DRUG:** Vincristine sulfate
- **RADIATION:** Whole-brain radiation therapy

## Key facts

- **NCT ID:** NCT01228331
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2019-12
- **Final completion:** 2024-11-20
- **Target enrollment:** 745 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228331, "Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01228331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*